Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells


Autoria(s): DOBROFF, Andrey S.; RODRIGUES, Elaine G.; JULIANO, Maria A.; FRIACA, Dayson M.; NAKAYASU, Ernesto S.; ALMEIDA, Igor C.; MORTARA, Renato A.; JACYSYN, Jacqueline F.; AMARANTE-MENDES, Gustavo P.; MAGLIANI, Walter; CONTI, Stefania; POLONELLI, Luciano; TRAVASSOS, Luiz R.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2010

Resumo

Malignant melanoma has increased incidence worldwide and causes most skin cancer-related deaths. A few cell surface antigens that can be targets of antitumor immunotherapy have been characterized in melanoma. This is an expanding field because of the ineffectiveness of conventional cancer therapy for the metastatic form of melanoma. In the present work, antimelanoma monoclonal antibodies (mAbs) were raised against B16F10 cells (subclone Nex4, grown in murine serum), with novel specificities and antitumor effects in vitro and in vivo. MAb A4 (IgG2ak) recognizes a surface antigen on B16F10-Nex2 cells identified as protocadherin beta(13). It is cytotoxic in vitro and in vivo to B16F10-Nex2 cells as well as in vitro to human melanoma cell lines. MAb A4M (IgM) strongly reacted with nuclei of permeabilized murine tumor cells, recognizing histone 1. Although it is not cytotoxic in vitro, similarly with mAb A4, mAb A4M significantly reduced the number of lung nodules in mice challenged intravenously with B16F10-Nex2 cells. The V(H) CDR3 peptide from mAb A4 and V(L) CDR1 and CDR2 from mAb A4M showed significant cytotoxic activities in vitro, leading tumor cells to apoptosis. A cyclic peptide representing A4 CDR H3 competed with mAb A4 for binding to melanoma cells. MAb A4M CDRs L1 and L2 in addition to the antitumor effect also inhibited angiogenesis of human umbilical vein endothelial cells in vitro. As shown in the present work, mAbs A4 and A4M and selected CDR peptides are strong candidates to be developed as drugs for antitumor therapy for invasive melanoma.

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Brazilian National Research Council (CNPq)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Graduate School, University of Texas at El Paso

Graduate School, University of Texas at El Paso

National Institutes of Health (NIH)[5G12RR008124]

U.S. National Institutes of Health (NIH)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

CNPq

Identificador

TRANSLATIONAL ONCOLOGY, v.3, n.4, p.204-217, 2010

1936-5233

http://producao.usp.br/handle/BDPI/28267

10.1593/tlo.09316

http://dx.doi.org/10.1593/tlo.09316

Idioma(s)

eng

Publicador

NEOPLASIA PRESS

Relação

Translational Oncology

Direitos

closedAccess

Copyright NEOPLASIA PRESS

Palavras-Chave #MOLECULAR-WEIGHT KININOGEN #HUMAN METASTATIC MELANOMA #PEPTIDE-BASED VACCINES #FULLY HUMAN-ANTIBODIES #HUMAN-TUMOR CELLS #MALIGNANT-MELANOMA #GROWTH-FACTOR #CANCER-IMMUNOTHERAPY #NEURAL CREST #CDR3 REGION #Oncology
Tipo

article

original article

publishedVersion